Category:

Non-Life

Latest

Etihad to provide Covid-19 insurance to passengers,cover medical and quarantine costs

Airlines around the world are trying to find ways to stimulate demand that has been shattered by the pandemic and expected to take years to recover.Medical costs of up to 150,000 euros ($177,000) and quarantine costs of up to 100 euro a day for 14 days will be covered by Etihad for its passengers who contract the disease within 31 days of first travel.

read more

Swiss Re sees positive outlook for renewals, further market hardening expected

Overall, Swiss Re expects the non-life insurance market to continue to grow, driven primarily by exposure growth. Swiss Re Institute forecasts a global growth rate of 3.3% in real terms for 2021. Other factors driving demand are the awareness, triggered by COVID-19, of the danger of being uninsured and the increasing frequency of weather-related events.

Swiss Re is making use of advanced technology to lead the way in underwriting. This includes enriching client exposure information with geospatial data to improve both the accuracy and speed of risk and loss assessments. In contracts, natural language processing complements human contract reviews, which helps to flag favourable vs potentially problematic clauses and generate new wording insights

read more

GIC Re incurs losses of Rs 557 cr in Q1 FY2020-21, sees higher underwriting losses and lower investment income

Global scenario for insurance industry for the FY 2020-21 has shown weak trends due to COVID-19 situation. GIC Re although has maintained its prominent position in Indian insurance sector, there has been reduction in business for the Q1 2020-21 partially due to strategic reduction of risk acceptance and partially due to reduction of overall direct premium in India, said the corporation..

GIC Re however expects to see rebound in business during the rest of the year. GIC Re’s gross premium for foreign business has shown a growth for the 1st Quarter 2020-21, added the corporation…

read more

India scaling up production of active pharmaceutical ingredients: Kant

Professor K Vijay Raghavan, Principal Scientific Advisor to the Government of India, said personalised medicines are the future in healthcare. Personalised medicine was till recently seen as a “fancy way of having individual-oriented medication” but today in India — due to the dramatic scaling up of telemedicine and a variety of tele-consulting ways — one is going to see personalised medicine at the grassroot-level in a population of more than a billion.

read more

“Pandemics,climate change,cyber top the current risk chart”:Munich Re

The coronavirus pandemic needs to be a lesson to us all: We must take action more rapidly and vigorously to ensure that we are not as unprepared as we were with COVID-19 for risks such as cyber attacks or climate change. It is possible to better safeguard against the financial consequences of such risks for the benefit of humanity. It needs to be clear that systemic risks like pandemics also require systemic countermeasures – for instance, the creation of state-backed risk pools to make uninsurable risks bearable,said Torsten Jeworrek,Member of the Board of Munich Re.

read more